02.09.2010 MorphoSys Initiates
Program Against Drug-Resistant MRSA Infections |
|
MorphoSys AG
(FSE: MOR; Prime Standard Segment, TecDAX) announced
today a new proprietary development program against novel infectious
disease targets. As part of this initiative, MorphoSys has signed a
license and collaboration agreement with UK-based Absynth Biologics,
providing access to novel target molecules associated with
Staphylococcus aureus
infections including MRSA (methicillin-resistant
S. aureus).
MorphoSys will generate antibodies using its proprietary HuCAL
PLATINUM antibody library which Absynth will test in relevant
disease models. MorphoSys will be solely responsible for the
development and partnering of the resulting compounds. Absynth will
receive an upfront payment and is eligible for development-dependent
milestone payments and royalties. Further financial details were not
disclosed.
 |
 |
|
|
|
|
31.08.2010 Vetter Opens New Sales
Office at Illinois Science + Technology Park in Suburban
Chicago |
|
In
keeping with its strategy of U.S. growth and expansion,
Vetter, a specialist in aseptically prefilled
drug-delivery systems, today announced that it has
opened a new sales office at the Illinois Science
+Technology Park in Skokie. The office will be managed
by Mr. Troy Carpenter, who was appointed as President of
Vetter Pharma International USA Inc. The new office
replaces its Yardley, Pennsylvania sales office, founded
in 1983 as Vetter Pharma-Turm Inc. The establishment of
the new office in the Midwest region, considered an
emerging “hotspot” in biotechnology, is consistent with
the company’s stated objective for worldwide growth by
focusing on the emerging pharmaceutical and
biotechnology market in North America. The office, to be
officially known as Vetter Pharma International USA
Inc., is a wholly owned subsidiary of
Vetter
Pharma International GmbH, which
is responsible for Vetter’s sales and marketing as well
as customer service functions. In 2009, Vetter announced
the creation of its first U.S. manufacturing facility,
also located at the Illinois Science + Technology Park.
The facility – an expansion of Vetter Development
Service – is scheduled to be operational in the
beginning of the fourth quarter of 2010.
|
 |
|
|
|
|
18.08.2010 CEVEC Signs Global License Agreement for Human CAP-T
Technology with Life Technologies |
|
CEVEC Pharmaceuticals,
the
developer of a novel human
protein expression system
derived from amniocytes,
announced today the signing of a
co-exclusive worldwide licensing
agreement with Life Technologies
Corporation, a leading provider
of innovative life science
solutions based in Carlsbad,
California. Under the terms of
the agreement, Life Technologies
and CEVEC will co-operate to
offer optimized expression kits
based on CEVEC’s proprietary
CAP-T cells to the global life
science research community. Life
Technologies will pay CEVEC a
signing fee and various
milestone payments and royalties
on sales of the future products.
Further details of the agreement
were not disclosed. CEVEC will
continue to expand its global
license business of the CAP® and
CAP-T® technologies for
commercial use and industrial
development purposes.
|
 |
|
|
|
|
16.08.2010 New Isolera™ UV-VIS Flash
Purification System Delivers Widest Wavelength Range Available to
Chemists |
|
Biotage
(STO: BIOT),
a leading developer of tools and technology for medicinal and
analytical chemistry, announces the introduction of the Isolera™
UV-VIS flash purification system. The UV-VIS system enables
detection of organic molecules with spectral absorbance between 200
nm and 800 nm making it the broadest wavelength detection flash
system available to chemists. The system provides detection capable
to near IR range. Applications for the UV-VIS system include natural
products (carotenoids, flavanoids, proanthocyanidins, etc.),
synthetic dyes, diagnostic dyes, and OLED chemicals.
|
 |
|
|
|
|
10.08.2010 Anavex Appoints
Contract Research Organizations to Initiate Phase I/IIa
Clinical Programs, Regulatory Strategies in
Alzheimer’s Disease |
|
Anavex Life Sciences Corp.
("ANAVEX") (OTCBB: AVXL)
today announced that it has signed a definitive
master services agreement with Genesis BioPharma
Group (“Genesis”) and
ABX-CRO
Advanced Pharmaceutical Services (“ABX-CRO”)
to begin clinical studies and regulatory filings
for ANAVEX 2-73, its lead compound for the treatment
of Alzheimer’s Disease.
|
 |
|
|
|
|
05.08.2010 MediGene AG Reports Financial
Results for First Six Months of 2010: Continuing
Increase in Total Revenue, Significant Reduction of
Loss |
|
In the first six
months of 2010, the biotech company
MediGene AG
(Frankfurt, Prime Standard, TecDAX)
increased total
revenue by 26% to EUR 25.2 million, and
reduced the loss on an EBITDA basis by
20% to EUR -5.4 million. The net loss
was reduced by 60% to EUR -3.3 million.
These results are reported in compliance
with IFRS (International
Financial Reporting Standards).
|
 |
|
|
|
|
04.08.2010 Glycotope Received Regulatory Approval for Glycooptimized
and Fully Human Glycosylated Antibody CetuGEX™ and Enrolls First
Patients in Clinical Trial |
|
Glycotope
GmbH, a leading glycobiology company,
has received regulatory approval by
German and Italian regulatory
authorities for a Phase I study of
Glycotope´s next generation antibody
CetuGEX™ (GT-MAB 5.2-GEX) for the
treatment of various solid cancers.
|
 |
|
|
|
|
02.08.2010 MorphoSys Announces
Clinical Milestone from Strategic Alliance |
|
MorphoSys AG
(FSE: MOR; Prime Standard Segment, TecDAX)
announced today that it will
receive a milestone payment from Novartis in connection with the
initiation of a phase 1 clinical trial of a HuCAL-derived, fully
human antibody in the therapeutic area of ophthalmology. Today's
news marks the entry of the third HuCAL-derived antibody into human
clinical trials in 2010, following the advancement of one program
each from the alliances with Novartis and Centocor Ortho Biotech
earlier this year.
|
|
|
|
|
|
28.07.2010 MorphoSys AG Reports Six Months
2010 Results |
|
MorphoSys AG
(FSE: MOR; Prime Standard Segment, TecDAX) today
announced its financial results for the six months
ending June 30, 2010 according to
International Financial Reporting Standards (IFRS).
Group revenues increased by 15 % to EUR 43.5 million
(H1 2009: EUR 37.9 million) and operating profit
increased by 26 % to EUR 8.3 million (H1 2009: EUR 6.6
million). Net profit amounted to EUR 5.9 million
(H1 2009: EUR 5.0 million), a gain of 18 % over the same
period of the previous year. As planned, MorphoSys
further increased its investment in proprietary research
and development to EUR 11.1 million (H1 2009: EUR 8.5
million). MorphoSys's cash position on June 30, 2010 was
EUR 152.1 million (December 31, 2009: EUR 135.1
million). The cash position at balance sheet date still
includes the outstanding up-front payment of approx.
EUR 10.5 million, which was paid to Xencor in early
July. The Company re-confirmed its full year guidance
for 2010.
|
|
|
|
|
|
26.07.2010 AbD Serotec Secures Exclusive
Worldwide License to Key Diagnostic Antibody
|
|
MorphoSys AG
(FSE: MOR; Prime Standard Segment, TecDAX)
announced today that its research and diagnostic antibodies unit AbD
Serotec has signed an exclusive license agreement with UCL Business
PLC (UCLB), the technology development company of University College
London (UCL). The agreement provides AbD Serotec with worldwide
exclusive access to a potent anti-PTH antibody for commercial use in
research and diagnostic applications. The anti-PTH antibody forms
the basis of an existing relationship between AbD Serotec and a
leading diagnostic company which markets clinical parathyroid
hormone assays.
|
|
|
|
|
 |
|
|
26.07.2010 Clontech Laboratories, Inc. & TET
Systems Announce the Broadening of Their License Agreement And the
Upcoming Launch of The New Tet-On® 3G™ Inducible Expression System |
|
Clontech
Laboratories, Inc., a wholly-owned subsidiary of
Takara Bio Inc., and TET Systems
(TET), a privately-held German biotech company based in Heidelberg,
today announced that they have signed an amendment to their existing
license agreement. Under the expanded license agreement, Clontech
obtains rights to develop, manufacture and commercialize novel Tet
Systems products as the Tet-On® 3G™ Inducible Expression System (www.clontech.com/teton3g
).
|
 |
|
|
|
|
21.07.2010 AiCuris Presents Mechanism of Action Investigations of
Its Novel Anti-HCMV Drug AIC246 at The International Herpesvirus
Workshop |
|
AiCuris announced today publication of
preclinical data on AIC246, at the International Herpesvirus
Workshop in Salt Lake City, Utah, USA from 24 – 29 July 2010. AIC246
is a novel anti-HCMV drug currently in clinical phase 2 testing.
|
 |
|
|
|
19.07.2010 MediGene sells full European rights for Eligard® to
Astellas for EUR 25 million and ongoing royalties
MediGene AG
(Frankfurt, Prime Standard, TecDAX)
announces the sale of full
European marketing and distribution
rights to Eligard®
(leuprolide acetate, for the
treatment of hormone-dependent prostate
cancer) to Astellas Pharma Europe Ltd.
(London, "Astellas"), previously
MediGene's European marketing partner
for Eligard®. MediGene
acquired these rights from TOLMAR
Therapeutics Inc. (formerly Atrix
Laboratories Inc.) in 2001. In return
for the Eligard® license,
MediGene will receive EUR 25 million in
cash from Astellas as well as royalties
on future product sales. For MediGene,
all future costs, obligations and risks
associated with the supply of Eligard®
to Astellas, as well all future
procurement costs and license payments
to TOLMAR, will cease within the next
months.
|
|
|
|
|
19.07.2010 Bionas® Adcon Reader for Impedance-based Cellular
Analysis Launched
Bionas GmbH announces the launch of its
new Bionas® adcon reader for impedance-based, cellular analysis. The
Bionas adcon reader technology is based on real-time monitoring of
cellular impedance, thus giving real-time data about cell adhesion,
membrane integrity, cellular morphology and cell proliferation for
applications in toxicology, oncology, receptor signaling as well as
the quality management of cells. Bionas technology allows for
the analysis of cellular behavior in real-time without the use of
any dyes or antibodies, thus avoiding the result being biased by the
manipulation of the cells during the assay. The Bionas adcon reader
consists of the Bionas plate station, the Bionas analyzer and a
control unit (PC) and offers easy handling in 96-well format for
laboratory research and HTS applications.
|
 |
|
|
|
|
|
|
bitop AG, a biotech company specializing
in the development of Ectoin-containing medical devices, reports
that Ectoin allergy nasal spray has been shown to significantly
reduce symptoms of acute allergic rhinitis in a two-week
observational, randomized, comparative crossover study with 50
patients suffering from acute allergic rhinitis. Based on this
study, bitop performed a clinical trial on eyes drops and nasal
spray in humans using an environmental exposure chamber (EEC) model.
The preliminary outcomes suggest a significant improvement of the
symptoms of allergic rhinitis and conjunctivitis.
|
 |
|
|
|
|
01.07.2010 MorphoSys Announces Clinical Milestone from Strategic
Alliance |
|
MorphoSys AG
(FSE: MOR; Prime Standard Segment, TecDAX) announced
today that it will receive a milestone payment from
Novartis in connection with the initiation of a phase 1
clinical trial, using a HuCAL-derived, fully human
antibody in the therapeutic area of musculoskeletal
diseases. Today's news represents the second
HuCAL-derived antibody to achieve this stage during the
course of 2010, following a clinical milestone hit as
part of the alliance with Centocor in June 2010.
|
|
|
|
|
|
24.06.2010 MediGene
reports additional phase II results of EndoTAG(TM)-1
for the treatment of triple receptor-negative breast
cancer |
|
The biotechnology company
MediGene AG
(Frankfurt, Prime Standard, TecDAX)
announces additional phase II clinical
trial results of the drug candidate
EndoTAGTM-1
for the treatment of triple
receptor-negative breast cancer. The
extensive data analysis of the three-arm
trial conducted in 140 patients confirms
a positive efficacy trend of EndoTAGTM-1
in combination with paclitaxel for the
treatment of this difficult to treat
type of cancer. The objective of the
trial was achieved, and the initial
conclusion of the preliminary data
published on May 6, 2010 was verified.
|
|
|
|
|
|
22.06.2010
MorphoSys Announces
Clinical Milestone |
|
MorphoSys AG
(FSE: MOR; Prime Standard Segment, TecDAX)
announced today that
it will receive a clinical milestone payment from
Centocor Ortho Biotech Inc. (formerly known as: Centocor,
Inc.) in connection with the initiation of a phase 1
clinical trial of a HuCAL-derived antibody in the
therapeutic area of inflammatory and autoimmune
diseases. The target against which the antibody is
directed is undisclosed.
|
|
|
|
|
|
22.06.2010 Bicoll and The European
Molecular Biology Laboratory (EMBL) Announce Results of Their Joint
Research Project on the Identification of Aurora Kinase Inhibitors |
|
The
Bicoll
GmbH,
a biopharmaceutical drug
discovery company specializing
in high-tech natural product
chemistry to identify novel
small molecules for drug
discovery and related innovative
fields and EMBL, the renowned
international and
inter-governmental research
organisation, focusing on
molecular biology and
biophysics, today announce the
successful completion of a joint
research project on the
identification of active
compounds as inhibitors of
aurora kinases.
|
 |
|
|
|
|
|
|
Protagen AG,
a specialist for in-vitro
diagnostics and GMP-compliant protein analysis, and Bayer Schering
Pharma AG, a global leading specialty pharmaceuticals company,
announced today the closing of a cooperation contract for discovery
of novel biomarkers in Endometriosis.
|
 |
|
|
|
|
26.05.2010 Pevion Biotech and CEVEC
Pharmaceuticals Sign Exclusive License Option Agreement
|
|
CEVEC Pharmaceuticals,
the German developer of a novel
human expression system derived
from amniocytes, announced today
the signing of an exclusive
license option agreement with
Pevion Biotech,
the Swiss vaccine company. The
agreement enables Pevion Biotech
to exclusively use CEVEC’s
transient CAP-T™ cell expression
technology to manufacture and
commercialize a protein antigen
for vaccination against a
widespread human infectious
disease.
|
 |
|
|
|
|
26.05.2010 ifp Institut für Produktqualität
Enters Global Cooperation with QIAGEN to Market its Food Tests |
|
The
Berlin-based diagnostics company ifp Institut für Produktqualität
has sold its molecular biological, PCR-based food test product line
to QIAGEN at a price not revealed.
QIAGEN
has purchased all the required patents and licences and will
immediately begin to market and distribute the newly acquired
portfolio of 70 molecular biological tests. With the support of this
powerful and experienced partner in food diagnostics ifp can now
make available its expertise in food analytics globally.
|
 |
|
|
|
|
25.05.2010 MorphoSys's Annual General
Meeting Approves All Agenda Items |
|
MorphoSys AG
(FSE: MOR; Prime Standard Segment, TecDAX)
announced today that at the Company's annual shareholder meeting,
which took place in Munich on Friday, May 21, 2010, its shareholders
approved all management proposals put to vote at the meeting.
|
|
|
|
|
|
17.05.2010 Elexopharm Enters Into
Cardiovascular Collaboration With Merck & Co.,
Inc |
|
ElexoPharm GmbH announced today a collaboration and
exclusive worldwide license agreement with Merck & Co., Inc. Whitehouse
Station, New Jersey USA (also known as MSD outside of the US and Canada)
through an affiliate to develop and commercialize novel candidates targeting aldosterone synthase for the potential treatment of cardiovascular disease.
|
 |
|
|
|
|
12.05.2010
MOLOGEN reaches further
important milestones |
|
MOLOGEN AG
has reached further important milestones
in the ongoing fiscal year: In March the company received approval from the
responsible health authorities in Germany and Austria to conduct a phase 2
clinical study with its cancer medicine MGN1703. It is expected that the
study will be initiated soon. First results from the phase 2 study will be
available in about nine or ten months following an intermediate analysis.
|
 |
|
|
|
|
10.05.2010
MediGene continues the global
licensure of Veregen® through agreements with GC Rise in China and
JS Bio Pharm in South Korea
|
|
The biotech company
MediGene AG
(Frankfurt, Prime Standard, TecDAX) has
signed two further license and supply
agreements for the commercialization and
marketing of
Veregen®.
These have been signed with GC-Rise
Pharmaceutical Co., Ltd. in China and
JS Bio Pharm Co., Ltd. in South Korea.
|
|
|
|
|
  |
|
|
07.05.2010
MediGene
AG reports on first quarter of 2010:total revenue
increased - cost constant |
|
In the first
quarter of 2010, the biotech company
MediGene AG
(Frankfurt: MDG, Prime Standard, TecDAX)
increased total revenue and kept its expenses
stable. The net loss increased compared to last
year's reporting period. Results are reported in
compliance with (International
Financial Reporting Standards).
|
|
|
|
|
|
30.04.2010 Aragen
Bioscience, Inc. and CEVEC Sign License Agreement
for Human CAP®
and CAP-TTM
Technology |
|
|
CEVEC Pharmaceuticals
(“CEVEC”), the developer of a novel human expression
system derived from amniocytes, and Aragen Bioscience,
Inc. (“Aragen Bioscience”), a California based contract
research and development organization, announced today
the signing of a strategic license agreement. This
license enables Aragen Bioscience to offer its clients
custom recombinant human cell lines expressing
biotherapeutic proteins and antibodies as well as the
transient and stable production of preclinical and
clinical grade material.
|
|
|
|
|
|
29.04.2010
GATC Subsidiary Lifecodexx AG Develops Tests for
Prenatal Diagnostics
|
|
|
LifeCodexx AG (www.lifecodexx.com
) has started operational research and development work
on clinically validated diagnostic tests by using Next
Generation Sequencing technologies. The work currently
focuses on the field of prenatal diagnostics. LifeCodexx
will utilize
GATC Biotech’s
20 years of experience as well as its sequencing
laboratory, which is the European leader with a total
capacity of more than 2 terabases per year.
|
 |
|
|
|
|
27.04.2010 MorphoSys AG Reports
Results for the First Quarter of 2010 |
|
MorphoSys AG
(FSE: MOR; Prime Standard Segment, TecDAX) today
announced its financial results for the three months
ending March 31, 2010 according to
International Financial Reporting Standards (IFRS).
Group revenues increased by 8 % to EUR 20.6 million
(Q1 2009: EUR 19.1 million) and operating profit was
EUR 4.7 million (Q1 2009: EUR 4.2 million). Net profit
amounted to EUR 3.2 million (Q1 2009: EUR 3.5 million).
As planned, MorphoSys further increased its investment
in proprietary research and development, to EUR 4.6
million (Q1 2009: EUR 4.1 million). MorphoSys's cash
position on March 31, 2010 was EUR 147.3 million
(December 31, 2009: EUR 135.1 million). The Company
re-confirmed its full year guidance 2010.
|
|
|
|
|
|
20.04.2010
MorphoSys to Host Q1 2010 Conference Call on April 27, 2010 |
|
MorphoSys AG
(FSE: MOR; Prime Standard Segment, TecDAX)
will publish its first three months'
2010 results on
April 27,
2010 at 7:00 a.m. CET. At 2:00 p.m. CET (1:00 p.m. BST, 8:00 a.m.
EDT), the Management Board of MorphoSys AG will host a public
conference call to present MorphoSys's financial results for the
first three months of 2010 and provide further details on the
Company's latest developments.
|
|
|
|
|
|
19.04.2010
New CFO Arnd Christ to
take up position at MediGene in April |
|
The biotech company
MediGene AG
(Frankfurt: MDG,
Prime Standard, TecDAX)
today announces that
the Company's new Chief Financial Officer Arnd Christ, whose
appointment was announced in March, will succeed Dr. Thomas Klaue on
April 19, 2010, and Dr. Klaue has therefore resigned with immediate
effect. The appointment of Mr Christ was scheduled for May 11, 2010,
and the change has become possible earlier because he has been able
to terminate his previous employment as Chief Financial Officer at
NovImmune AG in mid-April.
|
|
|
|
|
|
14.04.2010 BioGenes Says Generic HCP Assays
Provide Insufficient Sensitivity |
|
BioGenes GmbH
a supplier of GMP-compliant immunoassays and
antibodies, completed a study that documents the insufficient
sensitivity of an ELISA-based generic host cell protein (HCP) assay.
The results confirm the observation of several contract
manufacturers that generic HCP assays are only of limited use for
detection of HCPs during manufacturing processes. The continued use
of generic HCP assays may lead to insufficient process documentation
and finally to safety hazards for patients.
|
 |
|
|
|
|
06.04.2010 MOLOGEN AG receives
funding to develop a DNA vaccine against hepatitis B |
|
The DNA specialists from Berlin are
intensifying their work on developing innovative and improved
DNA-based vaccines. This is a response to a high demand - with an
interesting market potential.
The
Berlin biotech company
MOLOGEN AG
has received funding for the pre-clinical development of a
MIDGE®-based vaccine against hepatitis B. The project has already
commenced and is being carried out jointly with Synvolux
Therapeutics B. V., a company based in the Netherlands.
|
|
|
|
|
|
01.04.2010 MediGene
Signs Agreement with Meditrina for the Commercialization of Veregen®
in Greece and Cyprus
|
|
Today the biotech company
MediGene AG (Frankfurt: MDG,
Prime Standard, TecDAX) has signed a
license and supply agreement with Meditrina Pharmaceuticals for the
supply and commercialization of Veregen® in Greece and
Cyprus. Meditrina will promote and distribute Veregen®
for the treatment of genital warts in both territories.
|
|
|
|
|
|
30.03.2010 MOLOGEN looks back on a
very eventful and successful business year 2009 |
|
The business year 2009 was extremely eventful
for MOLOGEN
AG:
The development of the most promising product candidates has been
advanced decisively. All other planned activities and clinical
studies are financially secured up until 2011.
|
|
|
|
|
|
26.03.2010
MediGene appoints Arnd
Christ as Chief Financial Officeras Successor to Dr. Thomas Klaue
|
|
Today the biotech company
MediGene AG
(Frankfurt: MDG, Prime Standard, TecDAX)
today
announced that Chief Financial Officer Dr. Thomas Klaue will leave
the company for different opinions in strategic directions of the
company by mutual consent with the Supervisory Board in May 2010.
Dr. Klaue will resign from office after the Annual Shareholders'
Meeting on May 11, 2010, and his employment contract will cease in
June 2010. Arnd Christ has been chosen to succeed Dr. Klaue as Chief
Financial Officer. Mr. Christ has many years' management experience
in the biotech and pharmaceuticals industry, and has held his
current position as Chief Financial Officer at the Swiss
biotechnology company NovImmune since 2007.
|
|
|
|
|
|
26.03.2010 MediGene AG presents
future business plan at annual analyst conference |
|
Today the biotech company
MediGene AG
(Frankfurt: MDG, Prime Standard, TecDAX)
reported its results for the fiscal year 2009, and gave an outlook
for the fiscal year 2010. According to the forecast, MediGene
reduced the loss on an EBITDA basis in 2009, from approximately 25
million euros to approximately
19 million euros, with unchanged revenue of approximately 40 million
euros. The net loss also improved significantly in 2009, from
approximately 31 million euros in 2008 to 22 million euros this
year.
|
|
|
|
|
|
15.03.2010 MorphoSys Granted Further
Patent on its Core Antibody Technology in Japan |
|
MorphoSys AG
(FSE: MOR; Prime Standard Segment,
TecDAX) announced today that the Japanese Patent Office
has granted a new patent providing extended protection
for the Company's core technology HuCAL. The new patent
(JP 4436457) covers the production and design of an
antibody library based on phage display. Currently, the
Company is prosecuting more than 35 different
proprietary patent families worldwide, in addition to
about the same number of patent families the Company is
pursuing in cooperation with its partners.
|
|
|
|
|
|
24.02.2010 AbD Serotec Significantly Improves
Antibody Generation Process
MorphoSys AG
(FSE: MOR; Prime Standard Segment, TecDAX) )
today announced that its research and diagnostic antibody unit AbD
Serotec has demonstrated significant progress using the HuCAL-based
technology platform ...
|
 |
|
|
|
|
18.02.2010 MorphoSys and Galapagos
Expand Antibody Alliance
MorphoSys AG
(FSE: MOR; Prime Standard Segment, TecDAX) and Galapagos
NV (Euronext: GLPG) announce that they have expanded their antibody
alliance in bone and joint diseases. Based on the solid
progress made so far, the partners have agreed to add another
antibody target to the alliance, thereby increasing the total number
of programs to four.
|
|
|
|
|
|
17.02.2010
BioVaria Goes Europe: Marketplace for
Life-Science Inventions from Leading European Research Institutions
Ascenion GmbH
and its partners are pleased to announce the
forthcoming BioVaria 2010, to be held in Munich on 20 April 2010.
BioVaria is the only dedicated biopharmaceutical showcasing event
that presents licensing opportunities and spin-off projects from
leading research institutions and universities from all
over Europe to the biopharmaceutical industry.
|
 |
|
|
All rights reserved